- In March 2025, IDF (The International Diabetes Federation) recognized 1-hour oral glucose tolerance test (OGTT) as a more practical and sensitive option compared to a 2-hour OGTT, which requires overnight fasting followed by taking a sugar drink and waiting an additional 2 hours to undergo an additional blood sugar measurement
- In February 2025, a review published in the Journal of Clinical Endocrinology & Metabolism highlighted the exponential growth of diabetes management tools over the last decade, including continuous glucose monitors (CGM) and automated insulin delivery systems. While not directly GTTs, these advancements underscore the broader trend towards more sophisticated and continuous glucose monitoring, which can complement or even reduce the need for traditional GTTs in some contexts, offering more comprehensive insights into glucose dynamics.
- In September 2024, Midas Pharma received marketing authorization in Germany for their standardized oral glucose tolerance test (oGTT) products (50g/200ml and 75g/300ml solutions). This development signifies a focus on standardized, pharmaceutical-grade glucose solutions for GTTs, addressing concerns about consistency and quality in testing, particularly following incidents related to contaminated glucose solutions.
- In January 2022, F. Hoffmann-La Roche Ltd launched the Cobas pulse system, a revolutionary networked diagnostic device. While this occurred slightly before the requested timeframe, it's a significant indicator of the trend towards integrated, point-of-care blood glucose readings that can interact with digital health software. Such systems contribute to a more efficient and connected approach to glucose testing and management.
- In December 2022, Digostics introduced GTT@home, an oral glucose tolerance home testing solution now available in the UK via NHS Supply Chain. This innovative solution streamlines the diabetes screening workflow by allowing effective and accurate oral glucose tolerance testing directly at the patient's home. It addresses patient convenience and aims to increase patient throughput, signifying a shift towards decentralized and patient-centric diagnostic solutions in the GTT market
